|Day Low/High||12.72 / 13.84|
|52 Wk Low/High||9.08 / 39.00|
Upside - +43% (enters into agreement to be acquired by Turn/River Capital for $13.00/shr in cash valued at ~$570M) - +20% (FDA approves IGALMI (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipola...
Premarket movers: Upside - +157% (reports two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture) - +13% (The Phoenix Holdings Ltd. discloses 11.60% stake; appoints Josh Tech as Chief Operations Officer, effec...
The sector is deep in a stealth bear market, but there are reasons for optimism heading into 2022.
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
BioXcel Therapeutics and Albiero Pharma have promising prospects based on drugs in their pipelines.
This simple option strategy, which I continue to use with small-cap biotechs, is one of the easiest and cheapest risk mitigation approaches an individual can take.
I continue to put new money to work in BioXcel Therapeutics and GoHealth.
The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.
Putting cash to work on significant market pullbacks such as the one that occurred Thursday is a key element of the strategy.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
Stick to themes like biotechnology, SPACs, EV batteries, and others.
BioXcel Therapeutics and Avadel Pharmaceuticals are new additions to my personal portfolio based on their promising drug prospects.
Most notable is how the coronavirus issue is having no negative impact.